

# Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.8	89.6	(35.9-184.6)	Male	5	5.7	87.5	(28.2-204.2)
Female	2	2.6	nc	(nc-nc)	Female	5	4.5	111.7	(36.0-260.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.9	142.9	(57.2-294.3)
Female	35	32.6	107.5	(74.8-149.5)	Female	3	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	13	10.8	120.9	(64.3-206.8)	<b><u>Ovary</u></b>				
Female	10	9.0	111.7	(53.5-205.4)	Female	5	3.0	165.3	(53.3-385.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	33	33.2	99.3	(68.3-139.4)
Female	3	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.0	nc	(nc-nc)
Male	11	4.8	231.0	(115.1-413.3)	Female	1	1.0	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.4	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	6.1	114.0	(45.7-234.9)
Male	3	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.0	nc	(nc-nc)	Female	7	7.3	96.5	(38.7-198.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	129	115.6	111.5	(93.1-132.5)
Female	0	0.7	nc	(nc-nc)	Female	112	104.6	107.1	(88.1-128.8)
<b><u>Lung and Bronchus</u></b>									
Male	23	14.8	155.2	(98.3-232.9)					
Female	12	13.4	89.9	(46.4-157.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	24.6	85.3	(52.8-130.3)	Male	18	15.4	116.8	(69.2-184.5)
Female	7	9.1	76.6	(30.7-157.9)	Female	6	11.3	53.2	(19.4-115.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.7	126.5	(46.2-275.3)	Male	5	3.9	128.8	(41.5-300.6)
Female	2	3.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	23	13.5	170.0	(107.7-255.1)
Female	69	81.3	84.9	(66.1-107.5)	Female	10	11.2	88.9	(42.6-163.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.2	nc	(nc-nc)	Male	11	9.1	121.3	(60.5-217.0)
<b><u>Colon / Rectum</u></b>					Female	2	4.1	nc	(nc-nc)
Male	24	31.0	77.4	(49.6-115.2)	<b><u>Ovary</u></b>				
Female	25	31.0	80.8	(52.3-119.2)	Female	4	8.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.2	80.3	(25.9-187.3)	Male	9	7.6	117.8	(53.7-223.6)
Female	0	1.8	nc	(nc-nc)	Female	8	8.2	97.3	(41.9-191.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	77	86.9	88.6	(70.0-110.8)
Female	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	5.9	118.8	(47.6-244.8)
Male	10	12.3	81.0	(38.8-149.0)	Female	4	3.6	nc	(nc-nc)
Female	5	6.9	72.2	(23.3-168.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	3.6	223.1	(96.0-439.5)
Male	2	3.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	5	4.7	107.4	(34.6-250.7)
<b><u>Leukemia</u></b>					Female	6	12.8	46.9	(17.1-102.1)
Male	3	8.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.4	94.3	(34.4-205.2)	Female	24	17.9	133.7	(85.7-199.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	6.2	112.3	(45.0-231.4)	Male	320	320.4	99.9	(89.2-111.4)
Female	1	2.2	nc	(nc-nc)	Female	251	296.4	84.7	(74.5-95.8)
<b><u>Lung and Bronchus</u></b>									
Male	52	44.4	117.2	(87.6-153.8)					
Female	39	43.2	90.4	(64.3-123.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	6.9	116.2	(50.0-228.9)	Male	5	5.0	100.9	(32.5-235.4)
Female	3	2.4	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	29	28.8	100.7	(67.5-144.7)	Female	7	3.3	213.2	(85.4-439.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.3	nc	(nc-nc)
Male	10	9.4	106.5	(51.0-195.8)	<b><u>Ovary</u></b>				
Female	5	8.3	60.2	(19.4-140.5)	Female	3	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	40	28.5	140.5	(100.4-191.4)
Female	2	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.7	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.2	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	5.3	187.7	(89.8-345.2)
Male	4	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.9	nc	(nc-nc)	Female	7	6.3	110.9	(44.4-228.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	109	100.3	108.6	(89.2-131.1)
Female	0	0.6	nc	(nc-nc)	Female	105	94.1	111.6	(91.2-135.1)
<b><u>Lung and Bronchus</u></b>									
Male	10	13.0	76.9	(36.8-141.4)					
Female	13	12.2	106.4	(56.6-182.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gill

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	10	5.9	170.0	(81.4-312.7)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.1	115.5	(46.3-238.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.0	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	26	22.2	117.1	(76.5-171.6)
Female	0	0.1	nc	(nc-nc)	Female	22	19.6	112.2	(70.3-169.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.0	nc	(nc-nc)					
Female	6	2.6	230.9	(84.3-502.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	36.6	114.6	(82.6-154.9)	Male	30	23.2	129.0	(87.0-184.2)
Female	13	14.2	91.6	(48.7-156.6)	Female	27	18.4	146.7	(96.7-213.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	7.0	156.9	(78.2-280.8)	Male	4	5.9	nc	(nc-nc)
Female	7	5.8	121.2	(48.5-249.7)	Female	4	4.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	21	20.1	104.3	(64.5-159.5)
Female	122	137.4	88.8	(73.7-106.0)	Female	23	17.8	129.3	(81.9-194.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.4	110.5	(40.4-240.6)	Male	18	14.4	124.9	(74.0-197.5)
<b><u>Colon / Rectum</u></b>					Female	14	6.7	207.6	(113.4-348.4)
Male	40	46.8	85.5	(61.1-116.4)	<b><u>Ovary</u></b>				
Female	53	47.7	111.1	(83.2-145.3)	Female	10	13.4	74.6	(35.7-137.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	9.8	92.0	(42.0-174.6)	Male	9	11.6	77.7	(35.5-147.5)
Female	1	2.8	nc	(nc-nc)	Female	14	12.7	110.5	(60.4-185.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	135	140.1	96.3	(80.8-114.0)
Female	3	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	8.8	159.3	(87.0-267.3)
Male	21	19.1	109.8	(67.9-167.8)	Female	7	5.4	129.7	(52.0-267.3)
Female	18	11.4	158.3	(93.8-250.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	4.4	134.9	(49.3-293.6)
Male	8	5.6	142.4	(61.3-280.6)	<b><u>Thyroid</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	2	7.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	22	21.7	101.4	(63.5-153.5)
Male	14	12.6	110.8	(60.5-185.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	9.9	60.9	(22.2-132.5)	Female	29	31.0	93.5	(62.6-134.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	9.9	100.7	(48.2-185.1)	Male	524	491.9	106.5	(97.6-116.1)
Female	5	3.5	144.7	(46.6-337.7)	Female	500	481.9	103.8	(94.9-113.3)
<b><u>Lung and Bronchus</u></b>									
Male	85	67.8	125.4	(100.2-155.1)					
Female	79	69.2	114.1	(90.3-142.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	5	4.1	122.6	(39.5-286.1)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	12	15.6	76.9	(39.7-134.4)
Female	0	0.1	nc	(nc-nc)	Female	11	13.3	82.6	(41.2-147.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.1	nc	(nc-nc)					
Female	0	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	15.0	73.2	(36.5-131.0)	Male	10	10.2	98.0	(46.9-180.2)
Female	4	5.6	nc	(nc-nc)	Female	15	8.6	174.3	(97.5-287.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	8.8	79.1	(31.7-163.1)
Female	63	60.6	103.9	(79.9-133.0)	Female	8	7.4	108.1	(46.5-213.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.9	nc	(nc-nc)
Male	14	19.7	71.1	(38.9-119.3)	<b><u>Ovary</u></b>				
Female	22	18.9	116.6	(73.0-176.5)	Female	4	5.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	4.1	218.5	(99.7-414.7)	Male	7	4.8	145.3	(58.2-299.4)
Female	0	1.1	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	63	58.1	108.5	(83.3-138.8)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.7	nc	(nc-nc)
Male	11	8.3	131.8	(65.7-235.9)	Female	3	2.1	nc	(nc-nc)
Female	10	4.9	205.8	(98.5-378.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.6	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	6	3.3	179.5	(65.5-390.7)
<b><u>Leukemia</u></b>					Female	8	11.2	71.3	(30.7-140.6)
Male	7	5.6	125.5	(50.3-258.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.2	118.0	(38.0-275.3)	Female	14	13.5	103.7	(56.6-173.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.3	nc	(nc-nc)	Male	205	208.8	98.2	(85.2-112.6)
Female	2	1.4	nc	(nc-nc)	Female	211	206.1	102.4	(89.0-117.1)
<b><u>Lung and Bronchus</u></b>									
Male	27	28.0	96.5	(63.6-140.5)					
Female	29	28.0	103.7	(69.5-149.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.6	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	6	2.2	271.1	(99.0-590.0)	Female	3	3.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	34	24.4	139.1	(96.3-194.4)	Female	3	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.2	nc	(nc-nc)
Male	8	8.6	93.0	(40.1-183.3)	<b><u>Ovary</u></b>				
Female	5	7.4	67.9	(21.9-158.4)	Female	1	2.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	31	26.4	117.3	(79.7-166.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.6	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.0	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.3	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.6	nc	(nc-nc)	Female	7	5.6	124.5	(49.9-256.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	92	91.7	100.3	(80.9-123.1)
Female	0	0.6	nc	(nc-nc)	Female	79	82.1	96.3	(76.2-120.0)
<b><u>Lung and Bronchus</u></b>									
Male	16	12.3	129.8	(74.1-210.8)					
Female	8	11.2	71.1	(30.6-140.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	8	6.0	132.9	(57.2-261.9)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	6.4	109.9	(44.0-226.5)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	17	22.0	77.2	(44.9-123.6)
Female	0	0.1	nc	(nc-nc)	Female	21	19.6	107.4	(66.5-164.2)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.9	nc	(nc-nc)					
Female	1	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	10.1	108.4	(54.1-194.0)	Male	13	5.9	218.8	(116.4-374.1)
Female	6	4.2	143.0	(52.2-311.3)	Female	10	4.8	206.6	(98.9-379.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.3	113.6	(41.5-247.2)
Female	45	36.2	124.4	(90.7-166.5)	Female	5	5.1	98.1	(31.6-228.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.8	nc	(nc-nc)
Male	20	12.6	159.3	(97.3-246.1)	<b><u>Ovary</u></b>				
Female	17	14.4	117.8	(68.6-188.6)	Female	3	3.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	44	34.6	127.1	(92.3-170.6)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.4	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.1	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.8	nc	(nc-nc)	Female	7	8.0	87.3	(35.0-179.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	147	127.3	115.5	(97.6-135.8)
Female	2	1.0	nc	(nc-nc)	Female	146	132.7	110.0	(92.9-129.4)
<b><u>Lung and Bronchus</u></b>									
Male	22	18.0	122.2	(76.5-185.0)					
Female	24	19.4	123.5	(79.1-183.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	22.6	70.7	(40.4-114.8)	Male	4	13.5	nc	(nc-nc)
Female	9	9.4	95.7	(43.7-181.7)	Female	9	11.3	79.8	(36.4-151.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	0	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	11	11.9	92.2	(46.0-165.0)
Female	99	81.1	122.0	(99.2-148.6)	Female	10	11.5	86.9	(41.6-159.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	3.1	190.9	(69.7-415.5)	Male	12	7.9	151.7	(78.3-265.1)
<b><u>Colon / Rectum</u></b>					Female	2	4.2	nc	(nc-nc)
Male	20	28.0	71.3	(43.6-110.2)	<b><u>Ovary</u></b>				
Female	28	32.7	85.5	(56.8-123.6)	Female	5	8.2	61.3	(19.8-143.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	5.5	217.1	(112.0-379.2)	Male	8	6.9	115.2	(49.6-227.1)
Female	1	1.8	nc	(nc-nc)	Female	9	8.6	105.1	(48.0-199.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	63	76.1	82.8	(63.6-106.0)
Female	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	5.4	nc	(nc-nc)
Male	8	10.7	74.6	(32.1-147.0)	Female	4	3.8	nc	(nc-nc)
Female	5	6.9	72.8	(23.5-169.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	2.7	nc	(nc-nc)
Male	6	3.1	190.6	(69.6-414.9)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	5	3.8	132.2	(42.6-308.5)
<b><u>Leukemia</u></b>					Female	6	12.2	49.0	(17.9-106.6)
Male	5	7.7	65.1	(21.0-151.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	6.4	nc	(nc-nc)	Female	20	17.8	112.1	(68.5-173.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.5	90.5	(29.2-211.2)	Male	262	284.0	92.2	(81.4-104.1)
Female	3	2.3	nc	(nc-nc)	Female	281	299.4	93.9	(83.2-105.5)
<b><u>Lung and Bronchus</u></b>									
Male	55	39.8	138.1	(104.1-179.8)					
Female	39	42.9	90.8	(64.6-124.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.6	79.1	(28.9-172.1)	Male	5	5.7	87.4	(28.2-204.0)
Female	3	2.6	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	5	1.5	336.3	(108.4-784.7)	Female	2	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	44	33.4	131.8	(95.7-176.9)	Female	1	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	13	10.5	123.4	(65.6-211.0)	<b><u>Ovary</u></b>				
Female	10	8.9	112.2	(53.7-206.4)	Female	4	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	33	31.0	106.6	(73.3-149.7)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.9	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.5	330.5	(106.5-771.3)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	6.6	182.2	(94.0-318.2)
Male	1	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	10	7.2	139.1	(66.6-255.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	101	112.4	89.8	(73.2-109.1)
Female	1	0.7	nc	(nc-nc)	Female	131	106.3	123.3	(103.1-146.3)
<b><u>Lung and Bronchus</u></b>									
Male	9	14.3	63.0	(28.7-119.5)					
Female	15	13.1	114.6	(64.1-189.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.0	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	5	3.2	154.0	(49.6-359.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	23	23.9	96.3	(61.0-144.4)	Female	3	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.1	nc	(nc-nc)
Male	4	8.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	6.9	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.7	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	23	24.5	93.9	(59.5-140.9)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.5	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.3	138.4	(50.5-301.2)
Male	4	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.6	nc	(nc-nc)	Female	8	5.3	151.4	(65.2-298.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	83	85.8	96.7	(77.1-119.9)
Female	0	0.5	nc	(nc-nc)	Female	85	78.4	108.4	(86.6-134.0)
<b><u>Lung and Bronchus</u></b>									
Male	16	11.4	139.8	(79.8-227.0)					
Female	13	10.4	124.9	(66.4-213.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.5	80.0	(29.2-174.0)	Male	3	4.3	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	23	24.3	94.6	(60.0-142.0)	Female	4	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.2	nc	(nc-nc)
Male	15	9.1	165.1	(92.3-272.3)	<b><u>Ovary</u></b>				
Female	7	9.7	71.9	(28.8-148.2)	Female	5	2.4	205.9	(66.4-480.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	5	2.6	195.1	(62.9-455.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	28	24.5	114.4	(76.0-165.3)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.5	143.3	(46.2-334.5)
Male	2	2.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	5	5.4	93.1	(30.0-217.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	84	91.4	91.9	(73.3-113.7)
Female	1	0.7	nc	(nc-nc)	Female	101	89.3	113.1	(92.1-137.5)
<b><u>Lung and Bronchus</u></b>									
Male	5	13.2	38.0	(12.2-88.6)					
Female	15	13.0	115.1	(64.4-189.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Halifax

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	8.4	106.7	(48.7-202.7)	Male	5	5.4	91.9	(29.6-214.5)
Female	1	3.1	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	11	4.7	233.2	(116.3-417.3)
Female	27	32.2	83.9	(55.3-122.1)	Female	7	4.0	175.1	(70.1-360.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	6	3.4	178.0	(65.0-387.5)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	9	10.8	83.4	(38.1-158.4)	<b><u>Ovary</u></b>				
Female	11	10.2	107.5	(53.6-192.4)	Female	4	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	25	32.6	76.7	(49.6-113.2)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.0	nc	(nc-nc)
Male	10	4.5	224.1	(107.3-412.1)	Female	2	1.1	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.4	129.4	(51.8-266.7)
Male	2	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.2	nc	(nc-nc)	Female	5	7.3	68.4	(22.0-159.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	112	114.4	97.9	(80.6-117.8)
Female	0	0.8	nc	(nc-nc)	Female	111	110.1	100.8	(82.9-121.4)
<b><u>Lung and Bronchus</u></b>									
Male	14	15.6	89.7	(49.0-150.6)					
Female	20	15.7	127.8	(78.0-197.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	7.9	164.8	(87.7-281.8)	Male	12	5.3	226.1	(116.7-395.0)
Female	0	2.5	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.7	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.6	108.5	(35.0-253.2)
Female	36	28.9	124.7	(87.3-172.6)	Female	6	3.3	179.8	(65.7-391.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	16	10.3	155.5	(88.8-252.6)	<b><u>Ovary</u></b>				
Female	10	8.4	119.7	(57.3-220.1)	Female	7	2.7	258.2	(103.5-532.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	37	30.3	122.1	(85.9-168.3)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	0	4.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	6	2.3	266.1	(97.2-579.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	5.4	110.5	(40.3-240.5)
Male	5	2.9	171.9	(55.4-401.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	8	6.4	125.4	(54.0-247.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	127	108.9	116.6	(97.2-138.7)
Female	0	0.6	nc	(nc-nc)	Female	104	95.5	108.9	(89.0-131.9)
<b><u>Lung and Bronchus</u></b>									
Male	9	14.6	61.5	(28.1-116.8)					
Female	8	12.7	63.1	(27.1-124.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	6.0	100.3	(36.6-218.3)	Male	4	4.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	28	22.8	123.0	(81.7-177.7)	Female	4	2.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.1	nc	(nc-nc)
Male	8	7.8	102.6	(44.2-202.1)	<b><u>Ovary</u></b>				
Female	9	7.5	120.4	(54.9-228.6)	Female	1	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	27	24.2	111.5	(73.5-162.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.5	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	3.7	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.6	nc	(nc-nc)	Female	8	5.1	155.4	(66.9-306.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	72	83.2	86.6	(67.7-109.0)
Female	0	0.5	nc	(nc-nc)	Female	81	77.4	104.7	(83.1-130.1)
<b><u>Lung and Bronchus</u></b>									
Male	7	11.2	62.6	(25.1-128.9)					
Female	12	10.6	113.6	(58.6-198.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	17.3	57.8	(27.7-106.2)
Female	0	0.1	nc	(nc-nc)	Female	7	14.2	49.3	(19.8-101.6)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.3	nc	(nc-nc)					
Female	0	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	12.4	161.8	(98.8-250.0)	Male	11	8.7	126.0	(62.8-225.5)
Female	7	5.0	140.1	(56.1-288.7)	Female	9	7.4	122.3	(55.8-232.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.5	146.6	(73.1-262.4)
Female	46	55.1	83.5	(61.2-111.4)	Female	7	6.6	106.3	(42.6-218.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.3	nc	(nc-nc)	Male	1	5.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.6	nc	(nc-nc)
Male	19	16.7	114.1	(68.7-178.2)	<b><u>Ovary</u></b>				
Female	23	16.8	136.8	(86.7-205.2)	Female	11	5.2	210.8	(105.1-377.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	9	4.4	204.1	(93.1-387.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	56	52.3	107.1	(80.9-139.1)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.0	nc	(nc-nc)
Male	9	7.3	123.5	(56.3-234.4)	Female	0	1.8	nc	(nc-nc)
Female	5	4.4	114.4	(36.9-267.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.0	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	9.4	159.6	(89.3-263.3)
Male	4	4.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.7	134.6	(43.4-314.2)	Female	10	12.4	80.4	(38.5-147.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.8	nc	(nc-nc)	Male	181	179.8	100.6	(86.5-116.4)
Female	1	1.3	nc	(nc-nc)	Female	195	184.3	105.8	(91.5-121.8)
<b><u>Lung and Bronchus</u></b>									
Male	20	23.5	85.1	(52.0-131.5)					
Female	23	25.2	91.3	(57.8-136.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanson

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	8.3	120.8	(57.9-222.2)	Male	5	6.0	83.4	(26.9-194.6)
Female	5	2.9	172.5	(55.6-402.5)	Female	6	4.8	124.1	(45.3-270.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
Female	45	35.2	127.9	(93.2-171.1)	Female	7	4.0	175.8	(70.4-362.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.6	nc	(nc-nc)
Male	24	11.2	214.0	(137.0-318.4)	<b><u>Ovary</u></b>				
Female	11	9.8	112.1	(55.9-200.6)	Female	4	3.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	43	36.0	119.5	(86.5-161.0)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.1	nc	(nc-nc)
Male	6	5.0	119.7	(43.7-260.5)	Female	0	1.1	nc	(nc-nc)
Female	6	2.7	220.7	(80.6-480.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.5	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	6.6	228.9	(128.0-377.6)
Male	4	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	14	8.0	175.4	(95.8-294.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	146	122.9	118.8	(100.3-139.7)
Female	2	0.8	nc	(nc-nc)	Female	153	114.7	133.4	(113.1-156.3)
<b><u>Lung and Bronchus</u></b>									
Male	20	15.9	125.6	(76.7-194.0)					
Female	20	15.0	133.1	(81.3-205.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	15	10.3	145.8	(81.5-240.5)	Female	0	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	6	3.6	166.0	(60.6-361.3)	<b><u>Ovary</u></b>				
Female	2	3.5	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	4	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	12	10.7	111.9	(57.7-195.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	0.8	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	46	38.1	120.6	(88.3-160.8)
Female	0	0.3	nc	(nc-nc)	Female	36	36.1	99.8	(69.9-138.1)
<b><u>Lung and Bronchus</u></b>									
Male	7	5.2	134.4	(53.9-277.0)					
Female	5	5.1	97.8	(31.5-228.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harvard

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.5	109.0	(39.8-237.2)	Male	10	4.4	229.3	(109.8-421.8)
Female	0	1.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	19	20.5	92.8	(55.9-145.0)	Female	3	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	7	7.9	88.2	(35.3-181.8)	<b><u>Ovary</u></b>				
Female	8	5.2	154.0	(66.3-303.4)	Female	2	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.7	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	29	24.6	117.8	(78.9-169.2)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.4	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.7	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.2	nc	(nc-nc)	Female	7	4.6	150.6	(60.3-310.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	88	85.5	102.9	(82.5-126.8)
Female	0	0.4	nc	(nc-nc)	Female	59	63.2	93.3	(71.0-120.4)
<b><u>Lung and Bronchus</u></b>									
Male	6	10.6	56.9	(20.8-123.8)					
Female	4	7.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	41	27.0	151.8	(108.9-206.0)	Male	30	14.0	214.0	(144.4-305.6)
Female	8	10.3	77.7	(33.5-153.1)	Female	28	10.3	273.0	(181.3-394.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.8	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	6	3.3	182.4	(66.6-397.1)	Female	1	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	15	12.6	118.9	(66.5-196.2)
Female	88	79.0	111.4	(89.3-137.2)	Female	11	12.0	91.8	(45.7-164.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.6	nc	(nc-nc)	Male	9	7.7	117.5	(53.6-223.1)
<b><u>Colon / Rectum</u></b>					Female	4	4.2	nc	(nc-nc)
Male	26	31.5	82.6	(54.0-121.1)	<b><u>Ovary</u></b>				
Female	39	34.3	113.6	(80.8-155.3)	Female	8	8.1	98.8	(42.6-194.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	6.1	nc	(nc-nc)	Male	7	8.0	87.6	(35.1-180.5)
Female	0	2.0	nc	(nc-nc)	Female	14	9.3	150.8	(82.4-253.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	111	84.3	131.6	(108.3-158.5)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.2	nc	(nc-nc)
Male	8	11.2	71.6	(30.8-141.1)	Female	4	4.0	nc	(nc-nc)
Female	7	7.2	97.3	(39.0-200.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.5	336.9	(108.6-786.2)
Male	4	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	1.0	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	9.6	nc	(nc-nc)
Male	8	8.2	97.4	(41.9-191.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	6.5	nc	(nc-nc)	Female	22	17.8	123.8	(77.5-187.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	5.6	125.0	(50.1-257.7)	Male	367	312.9	117.3	(105.6-129.9)
Female	2	2.4	nc	(nc-nc)	Female	317	303.2	104.6	(93.4-116.7)
<b><u>Lung and Bronchus</u></b>									
Male	44	47.1	93.4	(67.9-125.4)					
Female	38	48.1	79.0	(55.9-108.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	4.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	25	15.8	158.6	(102.6-234.1)	Female	1	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.8	nc	(nc-nc)
Male	8	5.8	138.5	(59.6-272.9)	<b><u>Ovary</u></b>				
Female	8	5.5	146.5	(63.1-288.6)	Female	1	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	19	17.4	109.4	(65.8-170.8)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	2.4	206.5	(66.5-481.8)
Male	0	1.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.1	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	60	60.6	99.1	(75.6-127.5)
Female	0	0.4	nc	(nc-nc)	Female	62	55.1	112.6	(86.3-144.3)
<b><u>Lung and Bronchus</u></b>									
Male	6	8.4	71.3	(26.1-155.3)					
Female	6	8.0	75.2	(27.4-163.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	62	58.0	107.0	(82.0-137.1)	Male	39	37.1	105.2	(74.8-143.8)
Female	25	23.9	104.4	(67.6-154.2)	Female	30	32.4	92.5	(62.4-132.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	11.8	118.2	(64.5-198.3)	Male	6	9.2	65.1	(23.8-141.6)
Female	9	10.4	86.5	(39.5-164.1)	Female	5	7.8	64.0	(20.6-149.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	22	32.6	67.5	(42.3-102.2)
Female	199	228.6	87.1	(75.4-100.0)	Female	31	30.4	102.1	(69.3-144.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	9.8	71.5	(28.6-147.3)	Male	22	22.1	99.6	(62.4-150.9)
<b><u>Colon / Rectum</u></b>					Female	12	11.3	105.8	(54.6-184.7)
Male	89	73.6	121.0	(97.1-148.9)	<b><u>Ovary</u></b>				
Female	81	81.9	98.9	(78.5-122.9)	Female	27	22.5	120.2	(79.2-174.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	19	14.9	127.8	(76.9-199.6)	Male	21	18.1	115.9	(71.7-177.2)
Female	8	4.6	172.8	(74.4-340.5)	Female	18	21.5	83.8	(49.6-132.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	5.6	89.6	(28.9-209.1)	Male	201	206.9	97.2	(84.2-111.6)
Female	4	4.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	13.9	93.3	(49.6-159.6)
Male	29	29.7	97.6	(65.4-140.2)	Female	7	9.3	75.0	(30.1-154.6)
Female	18	19.0	94.9	(56.2-149.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	15	9.1	164.8	(92.2-271.8)
Male	7	8.5	82.3	(33.0-169.6)	<b><u>Thyroid</u></b>				
Female	5	2.6	194.9	(62.8-454.8)	Male	10	11.5	87.3	(41.8-160.6)
<b><u>Leukemia</u></b>					Female	29	39.1	74.2	(49.7-106.5)
Male	22	21.1	104.2	(65.2-157.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	17.5	97.0	(56.5-155.3)	Female	60	50.4	119.1	(90.9-153.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	15.1	99.4	(55.6-164.0)	Male	798	765.2	104.3	(97.2-111.8)
Female	8	5.9	135.5	(58.4-267.1)	Female	777	815.2	95.3	(88.7-102.3)
<b><u>Lung and Bronchus</u></b>									
Male	121	104.4	115.9	(96.2-138.5)					
Female	121	114.2	106.0	(87.9-126.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.1	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	13.0	69.3	(31.6-131.5)
Female	0	0.1	nc	(nc-nc)	Female	8	9.6	83.1	(35.8-163.7)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.7	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	24.5	40.8	(19.5-75.0)	Male	35	15.8	222.2	(154.7-309.0)
Female	15	9.8	153.1	(85.6-252.5)	Female	19	12.8	148.2	(89.2-231.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.8	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	13	13.6	95.4	(50.7-163.1)
Female	102	98.3	103.7	(84.6-125.9)	Female	17	12.4	137.0	(79.8-219.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	3.8	nc	(nc-nc)	Male	5	10.1	49.7	(16.0-115.9)
<b><u>Colon / Rectum</u></b>					Female	7	4.7	147.7	(59.2-304.3)
Male	33	31.5	104.6	(72.0-146.9)	<b><u>Ovary</u></b>				
Female	39	33.0	118.0	(83.9-161.4)	Female	6	9.5	63.1	(23.0-137.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.8	118.3	(50.9-233.1)	Male	9	7.9	114.6	(52.3-217.6)
Female	1	1.9	nc	(nc-nc)	Female	10	8.7	114.6	(54.9-210.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	99	97.7	101.3	(82.4-123.4)
Female	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	5.9	nc	(nc-nc)
Male	9	13.2	68.3	(31.2-129.6)	Female	2	3.7	nc	(nc-nc)
Female	10	8.0	124.6	(59.6-229.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.7	183.7	(59.2-428.7)
Male	1	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	6	4.7	127.0	(46.4-276.4)
<b><u>Leukemia</u></b>					Female	20	15.2	131.2	(80.1-202.7)
Male	9	8.6	104.9	(47.9-199.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	6.9	101.5	(40.7-209.1)	Female	19	22.4	84.7	(51.0-132.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.9	72.5	(23.4-169.1)	Male	311	335.6	92.7	(82.6-103.6)
Female	1	2.4	nc	(nc-nc)	Female	354	339.0	104.4	(93.8-115.9)
<b><u>Lung and Bronchus</u></b>									
Male	35	45.8	76.3	(53.2-106.2)					
Female	48	48.0	99.9	(73.7-132.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	12	6.8	177.3	(91.5-309.7)	Female	4	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	9	7.8	115.5	(52.7-219.2)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	3	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.3	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.4	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	33	26.4	124.8	(85.9-175.2)
Female	0	0.2	nc	(nc-nc)	Female	38	22.6	167.8	(118.7-230.3)
<b><u>Lung and Bronchus</u></b>									
Male	5	3.6	140.8	(45.4-328.6)					
Female	6	3.1	192.2	(70.2-418.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	13.1	99.5	(52.9-170.1)	Male	7	8.1	86.4	(34.6-178.0)
Female	7	4.7	147.6	(59.1-304.1)	Female	12	6.2	194.3	(100.3-339.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	2.5	244.2	(89.2-531.6)	Male	2	2.1	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.0	113.7	(49.0-224.0)
Female	53	46.3	114.4	(85.7-149.6)	Female	3	6.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	6	4.9	123.0	(44.9-267.7)
<b><u>Colon / Rectum</u></b>					Female	5	2.3	220.5	(71.0-514.5)
Male	16	16.4	97.7	(55.8-158.7)	<b><u>Ovary</u></b>				
Female	17	15.4	110.3	(64.2-176.7)	Female	3	4.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	3.4	263.4	(120.2-500.0)	Male	3	4.1	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	5	4.2	119.8	(38.6-279.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	41	49.2	83.4	(59.8-113.1)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.1	161.0	(51.9-375.6)
Male	8	6.6	120.6	(51.9-237.6)	Female	2	1.7	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	5	2.4	209.8	(67.6-489.6)
<b><u>Leukemia</u></b>					Female	5	7.4	67.3	(21.7-157.1)
Male	2	4.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.3	nc	(nc-nc)	Female	11	10.6	103.5	(51.6-185.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	180	172.9	104.1	(89.5-120.5)
Female	1	1.1	nc	(nc-nc)	Female	179	162.2	110.4	(94.8-127.8)
<b><u>Lung and Bronchus</u></b>									
Male	27	24.3	111.3	(73.3-162.0)					
Female	34	24.0	141.4	(97.9-197.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	19.1	83.8	(47.8-136.0)	Male	12	12.3	97.9	(50.5-171.1)
Female	5	6.9	72.7	(23.4-169.6)	Female	9	9.4	96.1	(43.8-182.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	5	3.1	161.4	(52.0-376.6)
Female	5	3.0	168.9	(54.4-394.2)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	8	10.7	75.0	(32.3-147.8)
Female	59	70.3	84.0	(63.9-108.3)	Female	10	8.8	113.3	(54.2-208.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.8	nc	(nc-nc)	Male	10	7.7	129.1	(61.8-237.4)
<b><u>Colon / Rectum</u></b>					Female	3	3.4	nc	(nc-nc)
Male	13	24.6	52.7	(28.1-90.2)	<b><u>Ovary</u></b>				
Female	20	23.4	85.3	(52.1-131.8)	Female	10	6.7	148.2	(71.0-272.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	11	6.1	180.8	(90.1-323.5)
Female	2	1.3	nc	(nc-nc)	Female	5	6.2	81.3	(26.2-189.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	79	73.2	108.0	(85.5-134.6)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.6	nc	(nc-nc)
Male	12	10.2	118.1	(61.0-206.4)	Female	1	2.6	nc	(nc-nc)
Female	2	5.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	2.2	269.8	(98.5-587.3)
Male	3	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	7	3.7	189.7	(76.0-391.0)
<b><u>Leukemia</u></b>					Female	15	11.4	132.0	(73.8-217.8)
Male	8	6.7	118.9	(51.2-234.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.9	nc	(nc-nc)	Female	10	15.7	63.7	(30.5-117.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	5.3	132.0	(52.9-272.0)	Male	249	258.0	96.5	(84.9-109.3)
Female	2	1.7	nc	(nc-nc)	Female	211	241.3	87.4	(76.0-100.1)
<b><u>Lung and Bronchus</u></b>									
Male	27	35.2	76.8	(50.6-111.7)					
Female	23	33.6	68.4	(43.3-102.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	8.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.4	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.1	109.4	(52.4-201.2)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.6	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	29	32.4	89.4	(59.9-128.4)
Female	0	0.2	nc	(nc-nc)	Female	23	25.7	89.4	(56.6-134.1)
<b><u>Lung and Bronchus</u></b>									
Male	4	4.2	nc	(nc-nc)					
Female	2	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	11.6	103.0	(53.2-180.0)	Male	9	8.5	105.5	(48.1-200.3)
Female	8	4.1	196.0	(84.4-386.1)	Female	7	6.8	102.8	(41.2-211.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	5	2.2	231.6	(74.6-540.6)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	7.3	68.6	(22.1-160.0)
Female	49	51.3	95.6	(70.7-126.4)	Female	9	5.6	160.7	(73.3-305.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	7	5.7	122.8	(49.2-252.9)
<b><u>Colon / Rectum</u></b>					Female	1	2.3	nc	(nc-nc)
Male	18	16.0	112.2	(66.5-177.4)	<b><u>Ovary</u></b>				
Female	12	13.8	86.9	(44.9-151.9)	Female	6	4.7	127.0	(46.4-276.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	6	3.9	154.5	(56.4-336.3)
Female	0	0.8	nc	(nc-nc)	Female	7	3.6	195.6	(78.4-403.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	69	50.8	135.9	(105.7-172.0)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.9	nc	(nc-nc)
Male	7	7.2	97.5	(39.0-200.8)	Female	2	1.5	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	14	9.4	149.5	(81.7-250.9)
Male	6	4.5	132.9	(48.5-289.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.2	nc	(nc-nc)	Female	11	11.5	95.5	(47.6-170.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	199	173.9	114.4	(99.1-131.5)
Female	3	1.1	nc	(nc-nc)	Female	172	163.9	105.0	(89.9-121.9)
<b><u>Lung and Bronchus</u></b>									
Male	20	22.4	89.2	(54.4-137.7)					
Female	16	21.2	75.4	(43.1-122.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	43.4	92.1	(65.8-125.4)	Male	13	25.9	50.2	(26.7-85.8)
Female	17	18.0	94.4	(55.0-151.2)	Female	20	22.5	89.0	(54.3-137.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	8.2	61.3	(19.8-143.1)	Male	6	6.7	89.8	(32.8-195.4)
Female	5	7.4	67.7	(21.8-158.0)	Female	5	5.8	86.3	(27.8-201.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	25	23.2	107.9	(69.8-159.3)
Female	149	157.8	94.5	(79.9-110.9)	Female	22	22.2	98.9	(61.9-149.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	6.5	139.3	(63.6-264.5)	Male	21	15.0	139.9	(86.6-213.9)
<b><u>Colon / Rectum</u></b>					Female	14	8.1	172.4	(94.2-289.3)
Male	51	53.5	95.3	(71.0-125.4)	<b><u>Ovary</u></b>				
Female	66	61.9	106.6	(82.4-135.6)	Female	12	15.9	75.6	(39.0-132.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	10.6	112.7	(58.2-196.9)	Male	18	13.3	135.3	(80.1-213.8)
Female	3	3.5	nc	(nc-nc)	Female	13	16.3	79.8	(42.5-136.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	136	147.7	92.0	(77.2-108.9)
Female	1	3.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	10.2	87.9	(40.1-166.9)
Male	14	20.7	67.7	(37.0-113.6)	Female	6	7.2	83.4	(30.5-181.6)
Female	17	13.4	126.5	(73.6-202.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	5.6	nc	(nc-nc)
Male	8	6.1	131.9	(56.8-259.9)	<b><u>Thyroid</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	6	7.4	81.3	(29.7-177.0)
<b><u>Leukemia</u></b>					Female	14	25.4	55.0	(30.1-92.3)
Male	14	15.3	91.4	(49.9-153.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	12.9	85.0	(42.4-152.1)	Female	40	34.8	114.9	(82.1-156.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	10.5	114.4	(59.1-199.9)	Male	506	549.8	92.0	(84.2-100.4)
Female	4	4.4	nc	(nc-nc)	Female	551	582.7	94.6	(86.8-102.8)
<b><u>Lung and Bronchus</u></b>									
Male	71	77.2	92.0	(71.8-116.0)					
Female	93	83.3	111.7	(90.1-136.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	7.2	167.8	(86.6-293.1)	Male	5	4.4	113.8	(36.7-265.6)
Female	1	2.8	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	22	26.3	83.6	(52.4-126.6)	Female	4	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	7	9.0	77.9	(31.2-160.6)	<b><u>Ovary</u></b>				
Female	14	9.5	147.5	(80.6-247.5)	Female	1	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.6	nc	(nc-nc)	Male	27	24.3	111.0	(73.1-161.5)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	6	3.5	169.9	(62.0-369.8)	Female	0	1.1	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.3	117.2	(37.8-273.4)
Male	3	2.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.0	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	87	91.4	95.2	(76.2-117.4)
Female	0	0.7	nc	(nc-nc)	Female	77	93.1	82.7	(65.2-103.3)
<b><u>Lung and Bronchus</u></b>									
Male	7	12.8	54.8	(22.0-113.0)					
Female	11	13.1	83.8	(41.8-150.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.4	85.5	(36.8-168.4)	Male	8	7.3	109.2	(47.0-215.3)
Female	3	3.5	nc	(nc-nc)	Female	7	6.3	112.0	(44.9-230.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	5	2.0	248.8	(80.2-580.6)	Female	3	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	6.3	110.6	(44.3-228.0)
Female	61	44.3	137.8	(105.4-177.0)	Female	4	4.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	14	13.3	105.3	(57.5-176.7)	<b><u>Ovary</u></b>				
Female	13	12.3	105.9	(56.3-181.0)	Female	4	4.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	44	38.6	114.0	(82.8-153.0)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.4	nc	(nc-nc)
Male	5	6.1	82.3	(26.5-192.0)	Female	0	1.3	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.1	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	17	8.9	191.5	(111.5-306.6)
Male	3	4.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.0	nc	(nc-nc)	Female	10	9.2	108.2	(51.8-199.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	126	141.7	88.9	(74.1-105.9)
Female	0	0.9	nc	(nc-nc)	Female	164	142.2	115.3	(98.4-134.4)
<b><u>Lung and Bronchus</u></b>									
Male	8	17.7	45.3	(19.5-89.2)					
Female	17	17.3	98.1	(57.1-157.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	2.9	208.6	(76.2-454.0)	Male	1	2.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	22	12.9	170.0	(106.5-257.4)	Female	2	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	5	4.1	121.3	(39.1-283.1)	<b><u>Ovary</u></b>				
Female	5	3.4	147.6	(47.6-344.5)	Female	0	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	15	12.6	118.7	(66.4-195.7)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	0.7	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.7	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	56	44.9	124.8	(94.3-162.1)
Female	0	0.3	nc	(nc-nc)	Female	50	41.0	121.9	(90.5-160.7)
<b><u>Lung and Bronchus</u></b>									
Male	10	5.6	179.1	(85.7-329.4)					
Female	4	4.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	18.7	48.0	(21.9-91.2)	Male	9	12.7	71.0	(32.4-134.9)
Female	7	7.1	98.9	(39.6-203.8)	Female	8	10.1	79.3	(34.1-156.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	6	10.9	54.9	(20.1-119.5)
Female	79	74.2	106.4	(84.3-132.7)	Female	12	9.2	130.8	(67.5-228.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.1	nc	(nc-nc)	Male	6	8.0	75.3	(27.5-164.0)
<b><u>Colon / Rectum</u></b>					Female	3	3.5	nc	(nc-nc)
Male	23	24.5	94.0	(59.5-141.0)	<b><u>Ovary</u></b>				
Female	28	23.4	119.5	(79.4-172.8)	Female	8	7.1	112.3	(48.4-221.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	5.2	nc	(nc-nc)	Male	10	6.0	165.6	(79.3-304.6)
Female	1	1.4	nc	(nc-nc)	Female	6	6.2	96.4	(35.2-209.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	73	75.0	97.3	(76.3-122.4)
Female	0	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.6	nc	(nc-nc)
Male	10	10.5	95.6	(45.8-175.8)	Female	6	2.6	232.3	(84.8-505.7)
Female	7	6.1	115.4	(46.2-237.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.0	nc	(nc-nc)
Male	5	3.0	165.6	(53.4-386.4)	<b><u>Thyroid</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	12.7	94.4	(48.7-164.8)
Male	8	6.8	117.6	(50.6-231.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.1	nc	(nc-nc)	Female	17	16.8	101.0	(58.8-161.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.4	nc	(nc-nc)	Male	243	262.4	92.6	(81.3-105.0)
Female	1	1.8	nc	(nc-nc)	Female	261	253.8	102.9	(90.8-116.1)
<b><u>Lung and Bronchus</u></b>									
Male	48	35.2	136.4	(100.6-180.9)					
Female	35	35.9	97.5	(67.9-135.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hull

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	12.2	114.8	(62.7-192.7)	Male	10	8.2	122.3	(58.6-225.0)
Female	5	4.2	118.0	(38.0-275.3)	Female	10	6.5	154.8	(74.1-284.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	8	7.0	114.4	(49.3-225.5)
Female	50	48.6	102.9	(76.4-135.6)	Female	10	5.6	177.4	(84.9-326.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	7	5.2	134.1	(53.7-276.4)
<b><u>Colon / Rectum</u></b>					Female	4	2.2	nc	(nc-nc)
Male	16	16.0	100.0	(57.1-162.3)	<b><u>Ovary</u></b>				
Female	20	14.0	142.5	(87.0-220.1)	Female	5	4.6	108.8	(35.1-254.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	54	49.7	108.6	(81.6-141.7)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.0	nc	(nc-nc)
Male	11	6.8	161.1	(80.3-288.3)	Female	0	1.5	nc	(nc-nc)
Female	7	3.8	183.1	(73.4-377.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	8.4	131.0	(65.3-234.4)
Male	5	4.3	116.2	(37.5-271.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	3.1	261.1	(112.4-514.4)	Female	14	11.2	124.7	(68.1-209.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	207	170.9	121.1	(105.2-138.8)
Female	1	1.1	nc	(nc-nc)	Female	207	160.1	129.3	(112.3-148.1)
<b><u>Lung and Bronchus</u></b>									
Male	31	23.0	134.7	(91.5-191.3)					
Female	27	22.0	122.7	(80.8-178.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	2.1	240.4	(77.5-560.9)	Male	3	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	8	7.9	101.6	(43.8-200.3)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	8.7	92.0	(39.6-181.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	40	30.1	132.9	(94.9-180.9)
Female	0	0.2	nc	(nc-nc)	Female	22	26.4	83.4	(52.3-126.3)
<b><u>Lung and Bronchus</u></b>									
Male	6	3.9	154.4	(56.4-336.1)					
Female	2	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	15.7	95.4	(53.3-157.3)	Male	15	10.1	148.9	(83.3-245.6)
Female	5	6.5	76.7	(24.7-179.0)	Female	14	8.3	168.1	(91.8-282.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	3.0	229.6	(92.0-473.1)	Male	4	2.6	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	8.7	125.8	(62.7-225.0)
Female	69	63.2	109.2	(84.9-138.2)	Female	13	8.2	159.0	(84.6-271.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	13	6.4	204.0	(108.5-348.8)
<b><u>Colon / Rectum</u></b>					Female	0	3.1	nc	(nc-nc)
Male	13	20.2	64.2	(34.1-109.8)	<b><u>Ovary</u></b>				
Female	33	22.2	148.8	(102.4-208.9)	Female	9	6.1	146.6	(66.9-278.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	11	5.8	188.4	(93.9-337.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	79	60.8	129.9	(102.8-161.9)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.8	132.3	(42.6-308.8)
Male	9	8.4	107.1	(48.9-203.3)	Female	4	2.5	nc	(nc-nc)
Female	4	5.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.8	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	5	3.0	164.3	(52.9-383.4)
<b><u>Leukemia</u></b>					Female	11	9.7	113.6	(56.6-203.3)
Male	12	5.4	220.8	(113.9-385.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.5	nc	(nc-nc)	Female	18	14.2	127.0	(75.2-200.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.4	nc	(nc-nc)	Male	249	213.0	116.9	(102.8-132.4)
Female	3	1.6	nc	(nc-nc)	Female	248	220.7	112.3	(98.8-127.2)
<b><u>Lung and Bronchus</u></b>									
Male	30	29.2	102.7	(69.2-146.5)					
Female	23	31.4	73.1	(46.3-109.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	13.8	65.0	(29.7-123.5)	Male	9	8.6	104.4	(47.6-198.2)
Female	12	5.2	229.3	(118.3-400.5)	Female	9	7.0	129.4	(59.0-245.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	13	7.6	171.5	(91.2-293.2)
Female	51	50.4	101.1	(75.3-133.0)	Female	5	6.6	75.8	(24.4-176.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	6	5.2	116.0	(42.4-252.5)
<b><u>Colon / Rectum</u></b>					Female	2	2.5	nc	(nc-nc)
Male	15	17.4	86.0	(48.1-141.8)	<b><u>Ovary</u></b>				
Female	20	17.9	111.6	(68.2-172.4)	Female	5	4.9	101.9	(32.8-237.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	5	4.3	115.9	(37.4-270.5)
Female	0	1.0	nc	(nc-nc)	Female	8	4.7	170.6	(73.5-336.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	61	49.3	123.7	(94.6-158.9)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.3	151.2	(48.7-352.8)
Male	6	7.0	85.7	(31.3-186.6)	Female	2	2.0	nc	(nc-nc)
Female	6	4.2	144.0	(52.6-313.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.8	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	8.4	83.8	(33.6-172.7)
Male	6	4.9	123.4	(45.0-268.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.8	131.8	(42.5-307.6)	Female	19	11.0	172.0	(103.5-268.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	190	180.5	105.3	(90.8-121.4)
Female	1	1.3	nc	(nc-nc)	Female	193	178.1	108.4	(93.6-124.8)
<b><u>Lung and Bronchus</u></b>									
Male	27	25.0	107.8	(71.0-156.9)					
Female	22	25.0	88.1	(55.2-133.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	10.3	96.9	(46.4-178.3)	Male	7	7.0	100.3	(40.2-206.6)
Female	6	4.0	150.8	(55.1-328.3)	Female	5	5.7	88.2	(28.4-205.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	6.0	83.1	(26.8-194.0)
Female	37	41.3	89.6	(63.1-123.5)	Female	5	5.1	97.5	(31.4-227.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	6	4.4	135.8	(49.6-295.6)
<b><u>Colon / Rectum</u></b>					Female	3	2.0	nc	(nc-nc)
Male	21	13.6	154.9	(95.9-236.9)	<b><u>Ovary</u></b>				
Female	13	13.7	94.9	(50.5-162.3)	Female	1	4.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	3.6	140.5	(45.3-327.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	47	40.8	115.3	(84.7-153.3)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	6	5.8	104.2	(38.1-226.8)	Female	2	1.6	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	1.5	388.5	(141.9-845.7)
Male	2	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	7.1	70.5	(22.7-164.6)
Male	2	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.0	nc	(nc-nc)	Female	7	9.1	77.3	(31.0-159.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	153	143.8	106.4	(90.2-124.6)
Female	0	1.0	nc	(nc-nc)	Female	131	141.6	92.5	(77.3-109.8)
<b><u>Lung and Bronchus</u></b>									
Male	21	19.2	109.4	(67.7-167.3)					
Female	23	19.2	119.8	(75.9-179.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	5.6	142.4	(61.3-280.6)	Male	1	4.3	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	23	21.2	108.6	(68.8-163.0)	Female	1	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	3	7.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	11	7.1	154.6	(77.1-276.6)	Female	2	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	30	22.8	131.7	(88.9-188.0)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.4	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	6	1.7	355.4	(129.8-773.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.5	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.8	131.0	(42.2-305.8)
Male	1	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	1.5	326.1	(105.1-761.0)	Female	8	4.7	171.2	(73.7-337.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	80	83.4	96.0	(76.1-119.4)
Female	0	0.5	nc	(nc-nc)	Female	94	73.4	128.0	(103.5-156.7)
<b><u>Lung and Bronchus</u></b>									
Male	14	10.5	133.9	(73.2-224.7)					
Female	14	9.9	142.0	(77.6-238.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	3.5	199.1	(79.7-410.1)	Male	5	2.3	217.7	(70.2-508.1)
Female	2	1.1	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	20	11.9	168.8	(103.0-260.7)	Female	4	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	5	4.5	109.9	(35.4-256.5)	<b><u>Ovary</u></b>				
Female	2	3.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	22	13.9	158.5	(99.3-239.9)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.9	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.0	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	67	48.3	138.8	(107.6-176.3)
Female	0	0.3	nc	(nc-nc)	Female	56	39.9	140.4	(106.0-182.3)
<b><u>Lung and Bronchus</u></b>									
Male	8	6.6	121.5	(52.3-239.4)					
Female	6	5.5	108.8	(39.7-236.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lawrence

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	52	54.3	95.7	(71.5-125.5)	Male	12	37.3	32.1	(16.6-56.2)
Female	16	22.2	71.9	(41.1-116.8)	Female	12	34.8	34.5	(17.8-60.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	13.5	118.6	(67.8-192.7)	Male	11	8.8	124.7	(62.2-223.2)
Female	10	11.9	84.0	(40.2-154.6)	Female	11	7.3	150.9	(75.2-270.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	24	33.0	72.6	(46.5-108.1)
Female	180	229.6	78.4	(67.4-90.7)	Female	26	29.5	88.1	(57.6-129.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	20	11.1	180.9	(110.4-279.4)	Male	17	22.1	76.9	(44.8-123.1)
<b><u>Colon / Rectum</u></b>					Female	8	11.3	70.8	(30.5-139.4)
Male	73	70.5	103.5	(81.1-130.1)	<b><u>Ovary</u></b>				
Female	79	76.5	103.2	(81.7-128.7)	Female	14	22.5	62.3	(34.0-104.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	14.3	76.9	(38.3-137.7)	Male	22	17.2	128.1	(80.3-194.0)
Female	2	4.3	nc	(nc-nc)	Female	29	19.9	146.1	(97.8-209.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	7.4	67.9	(21.9-158.6)	Male	218	198.6	109.7	(95.7-125.3)
Female	9	5.9	151.7	(69.2-288.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	18	13.3	135.7	(80.4-214.4)
Male	20	29.6	67.7	(41.3-104.5)	Female	6	8.7	69.2	(25.3-150.6)
Female	16	18.7	85.4	(48.8-138.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	12.5	nc	(nc-nc)
Male	14	8.2	170.9	(93.4-286.8)	<b><u>Thyroid</u></b>				
Female	3	2.5	nc	(nc-nc)	Male	10	12.7	78.9	(37.8-145.1)
<b><u>Leukemia</u></b>					Female	35	45.4	77.2	(53.7-107.3)
Male	20	22.5	88.8	(54.2-137.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	18	18.6	96.9	(57.4-153.2)	Female	45	50.1	89.7	(65.4-120.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	23	14.9	154.0	(97.6-231.1)	Male	729	750.9	97.1	(90.2-104.4)
Female	9	5.7	157.4	(71.8-298.8)	Female	698	809.4	86.2	(80.0-92.9)
<b><u>Lung and Bronchus</u></b>									
Male	107	98.6	108.6	(89.0-131.2)					
Female	97	107.4	90.3	(73.2-110.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lee

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	7.7	130.4	(62.4-239.8)	Male	4	4.7	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	5	3.5	141.5	(45.6-330.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.1	122.2	(39.4-285.1)
Female	25	26.4	94.8	(61.3-139.9)	Female	6	3.5	172.9	(63.1-376.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.3	nc	(nc-nc)
Male	12	9.5	125.8	(64.9-219.8)	<b><u>Ovary</u></b>				
Female	13	9.2	141.0	(75.0-241.1)	Female	1	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	30	28.5	105.2	(71.0-150.3)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	1.8	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.1	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	3	6.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	107	100.5	106.5	(87.3-128.7)
Female	0	0.7	nc	(nc-nc)	Female	93	93.2	99.7	(80.5-122.2)
<b><u>Lung and Bronchus</u></b>									
Male	21	14.1	148.6	(92.0-227.2)					
Female	17	13.7	124.4	(72.4-199.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	10.5	104.3	(52.0-186.6)	Male	5	7.0	71.5	(23.0-166.9)
Female	2	4.0	nc	(nc-nc)	Female	5	5.7	88.4	(28.5-206.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	41	40.4	101.4	(72.7-137.5)	Female	2	5.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.0	nc	(nc-nc)
Male	7	13.7	51.0	(20.4-105.1)	<b><u>Ovary</u></b>				
Female	16	13.5	118.8	(67.8-192.9)	Female	1	3.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	33	39.8	83.0	(57.1-116.5)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.6	nc	(nc-nc)
Male	7	5.7	123.4	(49.4-254.2)	Female	1	1.5	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.6	306.2	(98.7-714.6)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	7.1	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.9	nc	(nc-nc)	Female	13	9.0	144.8	(77.0-247.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	125	143.8	86.9	(72.3-103.5)
Female	0	1.0	nc	(nc-nc)	Female	134	140.4	95.5	(80.0-113.1)
<b><u>Lung and Bronchus</u></b>									
Male	27	19.3	139.6	(92.0-203.2)					
Female	31	19.4	159.8	(108.5-226.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	8.9	123.8	(61.7-221.5)	Male	11	4.9	224.1	(111.7-400.9)
Female	0	3.7	nc	(nc-nc)	Female	7	3.9	178.5	(71.5-367.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	40	29.8	134.3	(96.0-182.9)	Female	1	4.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.6	nc	(nc-nc)
Male	12	10.8	111.3	(57.4-194.4)	<b><u>Ovary</u></b>				
Female	12	12.9	92.8	(47.9-162.1)	Female	4	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	5	3.4	146.4	(47.2-341.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	32	29.2	109.5	(74.9-154.6)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.1	nc	(nc-nc)
Male	5	3.9	127.7	(41.2-298.0)	Female	0	1.5	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.8	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.4	nc	(nc-nc)	Female	8	6.6	121.2	(52.2-238.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	104	107.2	97.0	(79.3-117.5)
Female	1	0.9	nc	(nc-nc)	Female	112	112.4	99.6	(82.0-119.9)
<b><u>Lung and Bronchus</u></b>									
Male	8	15.4	51.8	(22.3-102.0)					
Female	12	16.8	71.6	(37.0-125.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	41.0	78.1	(53.4-110.2)	Male	24	26.7	89.9	(57.6-133.8)
Female	14	16.4	85.1	(46.5-142.8)	Female	13	22.8	56.9	(30.3-97.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	8.5	117.6	(56.3-216.2)	Male	5	6.6	75.8	(24.4-177.0)
Female	6	7.3	82.8	(30.2-180.1)	Female	4	5.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	16	23.3	68.8	(39.3-111.7)
Female	168	161.7	103.9	(88.8-120.8)	Female	21	21.0	100.0	(61.9-152.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	7.0	nc	(nc-nc)	Male	7	16.2	43.2	(17.3-89.1)
<b><u>Colon / Rectum</u></b>					Female	13	7.9	163.7	(87.1-280.0)
Male	56	52.4	106.8	(80.7-138.8)	<b><u>Ovary</u></b>				
Female	59	55.7	105.9	(80.6-136.5)	Female	20	15.8	126.9	(77.5-196.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	18	10.9	165.4	(98.0-261.4)	Male	14	13.0	108.1	(59.0-181.4)
Female	2	3.2	nc	(nc-nc)	Female	21	14.7	143.1	(88.6-218.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	129	153.8	83.9	(70.0-99.7)
Female	5	3.2	154.0	(49.6-359.4)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	9.9	101.3	(48.5-186.2)
Male	21	21.7	96.8	(59.9-148.0)	Female	7	6.3	111.0	(44.5-228.7)
Female	12	13.3	90.0	(46.5-157.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	6.5	93.0	(33.9-202.4)
Male	7	6.2	112.2	(44.9-231.1)	<b><u>Thyroid</u></b>				
Female	3	1.8	nc	(nc-nc)	Male	5	8.4	59.7	(19.2-139.2)
<b><u>Leukemia</u></b>					Female	23	28.0	82.0	(52.0-123.1)
Male	17	14.8	114.7	(66.8-183.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	12.0	91.6	(45.7-164.0)	Female	39	35.8	108.9	(77.4-148.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	11.1	72.3	(31.1-142.5)	Male	520	553.8	93.9	(86.0-102.3)
Female	5	4.1	123.3	(39.7-287.8)	Female	557	569.5	97.8	(89.9-106.3)
<b><u>Lung and Bronchus</u></b>									
Male	84	75.5	111.3	(88.8-137.8)					
Female	65	79.8	81.5	(62.9-103.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;